Published: The New England Journal of Medicine
Date:
Authors: William V Tamborlane, Margarita Barrientos-PĂ©rez, Udi Fainberg, Helle Frimer-Larsen, Mona Hafez, Paula M Hale, Muhammad Y Jalaludin, Margarita Kovarenko, Ingrid Libman, Jane L Lynch, Paturi Rao, Naim Shehadeh, Serap Turan, Daniel Weghuber, Timothy Barrett, Ellipse Trial Investigators
Abstract:
Metformin is the regulatory-approved treatment of choice for most youth with type 2 diabetes early in the disease. However, early loss of glycemic control has been observed with metformin monotherapy. Whether liraglutide added to metformin (with or without basal insulin treatment) is safe and effective in youth with type 2 diabetes is unknown.
Published: The New England Journal of Medicine
Date:
Authors: Vlado Perkovic 1 , Meg J Jardine 1 , Bruce Neal 1 , Severine Bompoint 1 , Hiddo J L Heerspink 1 , David M Charytan 1 , Robert Edwards 1 , Rajiv Agarwal 1 , George Bakris 1 , Scott Bull 1 , Christopher P Cannon 1 , George Capuano 1 , Pei-Ling Chu 1 , Dick de Zeeuw 1 , Tom Greene 1 , Adeera Levin 1 , Carol Pollock 1 , David C Wheeler 1 , Yshai Yavin 1 , Hong Zhang 1 , Bernard Zinman 1 , Gary Meininger 1 , Barry M Brenner 1 , Kenneth W Mahaffey 1 , CREDENCE Trial Investigators
Abstract:
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.
Published: The Journal of Pediatric Nursing
Date:
Authors: Shirleatha Lee 1 , Patricia Ann Cowan, Glenn T Wetzel, Pedro Velasquez-Mieyer
Abstract:
This ancillary, descriptive correlational study examined the effect of glucose regulation, blood pressure (BP), and their combined effects on cardiac autonomic function in 128 overweight-obese 11-18-year-olds.
Published: Journal of the American Academy of Nurse Practitioners
Date:
Authors: Claudia P Neira 1 , Margaret Hartig, Patricia A Cowan, Pedro A Velasquez-Mieyer
Abstract:
LINK TO RESEARCH https://pubmed.ncbi.nlm.nih.gov/19302694/ ABSTRACT Purpose: The purposes of this observational prospective study were (a) to identify the prevalence of undiagnosed impaired glucose metabolism (IGM) including impaired fasting glucose (IFG),...
Published: Clinical Pharmacology & Therapeutics
Date:
Authors: J A Batsis 1 , R E Nieto-Martinez, F Lopez-Jimenez
Abstract:
The metabolic syndrome (MetS) encompasses a constellation of metabolic abnormalities that are thought to place patients at higher risk for the development of diabetes and cardiovascular (CV) disease.
Published: The Journal of Pediatrics
Date:
Authors: Robert H Lustig 1 , Michele L Mietus-Snyder, Peter Bacchetti, Ann A Lazar, Pedro A Velasquez-Mieyer, Michael L Christensen
Abstract:
To assess the use of oral glucose tolerance testing (OGTT) to predict efficacy of insulin sensitization (metformin) or suppression (octreotide) because insulin resistance and insulin hypersecretion may impact pharmacotherapeutic efficacy in obese children.
Published: International journal of obesity and related metabolic disorders
Date:
Authors: R H Lustig 1 , S Sen, J E Soberman, P A Velasquez-Mieyer
Abstract:
Leptin resistance is a hallmark of obesity, but its etiology is unknown, and its clinical measurement is elusive. Leptin-sensitive subjects have normal resting energy expenditure (REE) at a low leptin concentration, while leptin-resistant subjects have a normal REE at a higher leptin concentration; thus, the ratio of REE:Leptin may provide a surrogate index of leptin sensitivity.
Published: International journal of obesity and related metabolic disorders
Date:
Authors: P A Velasquez-Mieyer 1 , P A Cowan, G E Umpierrez, R H Lustig, A K Cashion, G A Burghen
Abstract:
Obese African-American (AA) subjects have higher resting and stimulated insulin concentrations than obese Caucasians (C), which could not be explained by the severity of obesity or the degree of insulin sensitivity. We investigated whether differences in glucagon-like peptide-1 (GLP-1), the most potent incretin that regulates insulin secretion, might explain racial differences in insulin response.
Published: International journal of obesity and related metabolic disorders
Date:
Authors: P A Velasquez-Mieyer 1 , P A Cowan, K L Arheart, C K Buffington, K A Spencer, B E Connelly, G W Cowan, R H Lustig
Abstract:
Hyperinsulinemia is a common feature of many obesity syndromes. We investigated whether suppression of insulin secretion, without dietary or exercise intervention, could promote weight loss and alter food intake and preference in obese adults.